Healthcare Services

Global Immunoglobulin A IgA Vasculitis Market Report 2026–2035 Highlighting Expansion Outlook and Forecast Opportunities

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Immunoglobulin A IgA Vasculitis Market Between 2026 And 2030?

The immunoglobulin a iga vasculitis market has witnessed substantial growth over recent years. It is anticipated to expand from $1.63 billion in 2025 to $1.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.5%. This historical growth can be attributed to an improved clinical understanding of iga-mediated autoimmune disorders, an increase in the diagnosis of pediatric vasculitis cases, broader utilization of corticosteroids and immunosuppressants, the expansion of hospital-based autoimmune care, and growing nephrology clinical expertise.

The immunoglobulin a iga vasculitis market is projected to undergo significant expansion in the coming years. By 2030, its valuation is expected to reach $2.21 billion, exhibiting a compound annual growth rate (CAGR) of 6.2%. This anticipated growth can be attributed to increased research into novel immunomodulatory drugs, the rising adoption of personalized autoimmune therapies, a growing emphasis on long-term renal protection, the expansion of biologic treatment pipelines, and improvements in diagnostic imaging and biopsy techniques. Prominent trends for this period include a heightened focus on early and accurate disease diagnosis, the increasing use of targeted immunosuppressive therapies, the growing application of biomarker-based disease monitoring, the expansion of personalized treatment approaches, and an enhanced emphasis on renal outcome management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24567&type=smp

What Drivers Are Influencing The Immunoglobulin A IgA Vasculitis Market?

The immunoglobulin A (IgA) vasculitis market is projected to expand due to the increasing occurrence of autoimmune diseases. Autoimmune conditions involve the body’s immune system attacking its own healthy components, instead of defending against pathogens. The growing incidence of these disorders is largely attributable to increased exposure to pollutants, which can disrupt immune regulation and provoke abnormal responses. Immunoglobulin A (IgA) vasculitis contributes to addressing autoimmune diseases by initiating an immune response that leads to inflammation in small blood vessels, thereby assisting in comprehending and potentially treating various autoimmune conditions. For example, as reported by the Vasculitis Foundation, a US-based non-profit organization, in February 2024, the annual incidence of IgA vasculitis in U.S. adults is approximately 2 cases per 100,000, though global rates exhibit wide variation, ranging from about 60 to 550 cases per million. Consequently, the rising prevalence of autoimmune diseases is fostering the growth of the immunoglobulin A (IgA) vasculitis market.

Which Market Segments Are Examined In The Immunoglobulin A IgA Vasculitis Market Study?

The immunoglobulin a iga vasculitis market covered in this report is segmented –

1) By Treatment Type: Medications, Plasma Exchange, Supportive Care, Immunosuppressive Therapy

2) By Diagnosis Method: Blood Tests, Urinalysis, Imaging Studies, Biopsy

3) By Route Of Administration: Oral, Injectables

4) By End User: Hospitals, Specialty Clinics, Homecare Settings

Subsegments:

1) By Medications: Corticosteroids, Immunosuppressants, Cyclophosphamide, Azathioprine, Mycophenolate Mofetil

2) By Plasma Exchange: Therapeutic Plasma Exchange, Plasma Filtration

3) By Supportive Care: Pain Management, Kidney Function Support, Blood Pressure Management

4) By Immunosuppressive Therapy: Methotrexate, Rituximab

Which Trends Are Shaping The Future Of The Immunoglobulin A IgA Vasculitis Market?

Companies prominently involved in the immunoglobulin A (IgA) vasculitis market are directing their efforts towards creating advanced treatments, such as targeted biologics and immunomodulators, with the goal of lessening inflammation and avoiding renal complications. These targeted biologics and immunomodulators represent sophisticated therapeutic approaches that adjust specific immune pathways to diminish inflammation and prevent immune-mediated harm in IgA vasculitis. As an illustration, in April 2025, Novartis AG, a pharmaceutical company headquartered in Switzerland, secured approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) for managing primary immunoglobulin A nephropathy (IgAN). Vanrafia is an oral, once-daily, selective endothelin A receptor antagonist formulated to decrease proteinuria in adults with primary IgAN who are susceptible to rapid disease advancement. It can be seamlessly added to existing supportive care programs without requiring a risk evaluation and mitigation strategy (REMS).

Who Are The Primary Competitors In The Immunoglobulin A IgA Vasculitis Market?

Major companies operating in the immunoglobulin a iga vasculitis market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Intas Pharmaceuticals Ltd, Zydus Lifesciences Limited, Biogen Inc, Chugai Pharmaceutical Co Ltd, CSL Behring, AbbVie Inc, Johnson & Johnson, Bristol-Myers Squibb Company, UCB SA, Sanofi, GSK plc, Astellas Pharma Inc, Teva Pharmaceuticals USA Inc, Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co Ltd, Visterra Inc, Selecta Biosciences, Jiangsu HengRui Medicine Co Ltd, Travere Therapeutics Inc, Everest Medicines Ltd

Read the full immunoglobulin a iga vasculitis market report here:

https://www.thebusinessresearchcompany.com/report/immunoglobulin-a-iga-vasculitis-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Immunoglobulin A IgA Vasculitis Market?

North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin a iga vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Immunoglobulin A IgA Vasculitis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24567&type=smp

Browse Through More Reports Similar to the Global Immunoglobulin A IgA Vasculitis Market 2026, By The Business Research Company

Immunodiagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report

Veterinary Autoimmune Disease Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/veterinary-autoimmune-disease-therapeutics-global-market-report

Intravenous Immunoglobulin Global Market Report

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795